Biological Information

Background Information:

Adrenoreceptors belong to the superfamily of G protein-coupled seven transmembrane proteins. G-protein-coupled receptors constitute one of the major signal transduction systems in eukaryotic cells. Coding sequences for these receptors, in those regions believed to contribute to the agonist-antagonist binding site, are strongly conserved across mammalian species. Adrenoreceptors are found in most peripheral tissue and within the central nervous system. .

No. of Assays on Panel:

2

Assays on Panel:

Family

GPCR

Name

Item

302110-0

Protein

alpha2A

Organism

Human

Assay Sub Type

GTPgammaS

Family

GPCR

Name

Item

302110-1

Protein

alpha2A

Organism

Human

Assay Sub Type

GTPgammaS

Family:

GPCR

Sub Family:

Adrenoceptor

Class:

Class A

Protein Name:

alpha2A

Uniprot Number:

P08913

Protein Aliases:

alpha-2AAR subtype C10| alpha-2A-adrenergic receptor

Gene Name:

ADRA2A

Gene ID:

150

Gene Aliases:

ADRA2R|ADRAR

Accession Number:

NM_000681

Organism:

Human

Construct Details:

Full Length, Recombinant

Cell Type:

Chem-1

Assay Information

Assay Type:

Functional

Assay Sub Type:

GTPgammaS

Functional Mode:

Agonist & Antagonist

Detection Method:

Radiometry

Measured Response:

Scintillation

Testing Information

Procedure Summary:

Human recombinant adrenergic α2A receptors expressed in Chem-1 cells are used. Test compound is preincubated with 0.018 mg/ml‡ membranes and 3 µM GDP for 20 minutes at 25°C in modified HEPES buffer pH 7.4, then SPA beads are added for another 60 minutes at 30°C. The reaction is initiated by 0.3 nM [35S]GTPγS for an additional 30 minute incubation period. Test compound-induced increase of [35S]GTPγS binding by 50 percent or more (≥50%) relative to 10 µM UK 14,304 response indicates possible adrenergic α2A receptor agonist activity. Test compound-induced inhibition of 0.1 µM UK 14,304-induced increase of [35S]GTPγS binding response by 50 percent or more (≥50%) indicates receptor antagonist activity. Compounds are screened at 10, 1, 0.1, 0.01 and 0.001 µM. Note: ‡Membrane protein may change from lot to lot, the concentration used will be adjusted if necessary.

Incubation:

30 min at 30°C

Control Inhibitor:

Yohimbine

Control Activator:

Brimonidine

Criteria For Significance:

≥ 50% Increase in bound [35S]GTPgammaS relative to UK-14304 response, ≥ 50% Inhibition of UK-14304-induced bound [35S]GTPgammaS

Test Concentration / Dose:

Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM

Test Sample Requirements:

75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)

Minimum Order Quantity:

16

Turnaround Time

Standard:

20 Business Days

Reference Compound Data

PubChem ID

2435

Name

Brimonidine

Measurement

0.0087μM - EC50

PubChem ID

8969

Name

Yohimbine

Measurement

0.058μM - IC50

Clinical Relevance

Therapeutic Area:

Cardiovascular

Adverse / Beneficial Action:

Adrenergic a2A receptor agonist may cause bradycardia and hypotension, inhibit insulin secretion resulting in hyperglycemia; antagonist may cause hypertension and exacerbate heart failure

Additional Information

Brand:

LeadHunter

Testing Location:

Taiwan - Taipei

RELATED SOLUTIONS

Item: 302110-0
Item: 302110-1
Item: 203630